Healthcare professionals administering retatrutide within clinical trial settings must follow the trial's specific IMP storage protocol and any associated temperature monitoring requirements, which supersede all general guidance provided here
Additionally, we have identified eight new adverse events (AE) which include ketosis, euglycemic diabetic ketoacidosis, pancreatic cancer, sixth cranial nerve palsy, hyperglycemic hyperosmolar nonketotic syndrome, elevated glycated hemoglobin, positional dizziness, and belching
The next stage will focus on diagnosing the biological drivers of obesity and matching patients to the right combination of medications, behavioral support, and possibly advanced therapies
This ensures a level of personalization and safety that general diet plans simplycan't provide
Zhang C, Candia AA, Sferruzzi-Perri AN